Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
AGTC is a clinical-stage biotechnology company that uses a proprietary gene therap...
AGTC is a clinical-stage biotechnology company ...
Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized aut...
Cyclacel's founding scientist, Professor Sir Da...
Oramed Pharmaceuticals (NASDAQ: ORMP) was established in 2006, and has developed a...
Oramed Pharmaceuticals (NASDAQ: ORMP) was estab...
Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercializa...
Soleno Therapeutics, Inc. (Soleno) is focused o...
Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on ...
Syndax Pharmaceuticals, Inc. is a late-stage bi...
La Jolla Pharmaceutical Company is a publicly traded biopharmaceutical company foc...
La Jolla Pharmaceutical Company is a publicly t...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company d...
VBI Vaccines Inc. (Nasdaq: VBIV) is a commercia...
Join the National Investor Network and get the latest information with your interests in mind.